The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
Mayo Clinic · NCT05876923
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–80 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 70
- US sites recruiting
- 2
- Study start
- June 12, 2023
- Record last updated
- April 9, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients with indolent non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring hospitalization and an increased risk of secondary non-blood-based (hematologic) cancers. Increasing CLL patients overall physical fitness levels, through exercise during the observation stage, may provide a realistic approach means to increase survival, decrease treatment-related side effects, and improve immune function. Information learned from this study may help researchers determine whether a particular exercise regimen can be used to strengthen the immune system of indolent NHL and CLL patients, delay time to disease progression, assess the need for treatment, and assess infection rates.
Being studied: Biospecimen Collection; Cardiopulmonary Exercise Testing; Dual X-ray Absorptiometry; Electronic Health Record Review; Exercise Intervention; Physical Examination; Questionnaire Administration; Spirometry; Physical Performance Testing; Best Practice
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Indolent Non-hodgkin Lymphoma
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- English speaking
- Between the ages of 18-80
- Histologically confirmed diagnosis of indolent non-Hodgkin lymphoma (NHL) will be required to participate in Aim 2 (CLL/SLL only), aim 3 and 4 (indolent NHL) and aim 5 (indolent NHL) of this study
Exclusion Criteria
- Healthy subjects participating in Aim 1 will be excluded if they have known cardiovascular or pulmonary disease (e.g. heart disease, coronary artery disease, chronic obstructive pulmonary disease [COPD], asthma, etc.) an orthopedic or musculoskeletal limitation which would limit ability to exercise or are a current or former smoker
- Indolent NHL individuals receiving treatment must have least 8 weeks of planned treatment remaining and those who have already received treatment must be at least 6 months post and have no planned treatments during the 12-week intervention period to be eligible. Individuals that are participating prior to receiving treatment must not have any scheduled treatments during their participation. Individuals will be excluded if they have uncontrolled hypertension, cardiac illness, or are not approved by their oncologist to participate
Recruiting US locations
Mayo Clinic in Arizona
Scottsdale, AZ 85259
Site contact: Clinical Trials Referral Office · 855-776-0015 · mayocliniccancerstudies@mayo.edu
Mayo Clinic in Rochester
Rochester, MN 55905
Site contact: Clinical Trials Referral Office · 855-776-0015 · mayocliniccancerstudies@mayo.edu
Study contacts (from the official record)
- Clinical Trials Referral Office · 855-776-0015 · mayocliniccancerstudies@mayo.edu
- Courtney Wheatley-Guy, PhD · 480-301-8976 · wheatley.courtney@mayo.edu
Similar studies in Arizona
All healthy volunteers studies in Arizona →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Developing Biomarkers of Dietary Intake: Dose Dependent Measurement of Sugar Intake
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Location
- Phoenix, AZ
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
AstraZeneca
- Location
- Chandler, AZ + 2 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingHealthy volunteersPhase 1
A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation
Vertex Pharmaceuticals Incorporated
- Location
- Tempe, AZ
- Eligibility basics
- Ages 18–55 · Men only
- RecruitingHealthy volunteersPhase 1
A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult Participants
Epygenix
- Location
- Tempe, AZ
- Eligibility basics
- Ages 18–55